People: Proteome Sciences PLC (PRM.L)

PRM.L on London Stock Exchange

37.50GBp
19 Sep 2014
Price Change (% chg)

1.25p (+3.40%)
Prev Close
36.75p
Open
37.25p
Day's High
38.00p
Day's Low
36.25p
Volume
100,550
Avg. Vol
276,109
52-wk High
47.00p
52-wk Low
27.00p

Search Stocks

Summary

Name Age Since Current Position

Christopher Pearce

50 2014 Executive Chairman of the Board, Chief Executive Officer

James Malthouse

Finance Director, Company Secretary, Executive Director

Ian Pike

2010 Chief Operating Officer, Executive Director

Malcolm Ward

2011 Chief Technical Officer - London Research Facility

Glenn Barney

2011 Vice President - Business Development, USA

Josef Schwarz

2011 Head - Projects & Production, Proteome Sciences R&D

Gee See Chee

Director of Personalised Medicine

William Dawson

Non-Executive Director

Roger McDowell

58 2014 Non-Executive Director

Biographies

Name Description

Christopher Pearce

Mr. Christopher D. J. Pearce is Executive Chairman of the Board, Chief Executive Officer of Proteome Science PLC. Christopher Pearce has built the Group since inception and has been responsible for the formulation and implementation of strategy, collaborative and licensing agreements, and intellectual property. He was co-founder and Executive Chairman of Fitness First plc, the international fitness chain.

James Malthouse

Mr. James L. Malthouse is Finance Director, Company Secretary, Executive Director of Proteome Science PLC. James Malthouse joined the Group in 1993 and is a Chartered Accountant with banking and corporate finance experience. He was Chairman and Finance Director of Unigroup plc and Finance Director of Harcourt Group plc..

Ian Pike

Dr. Ian H. Pike is Chief Operating Officer, Executive Director of Proteome Sciences PLC. Ian Pike has over 20 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Wellcome Diagnostics as a research group leader and spent eight years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialisation of a wide portfolio of technologies related to the biomedical sector. Most recently, Ian worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the US..

Malcolm Ward

Dr. Malcolm Ward is Chief Technical Officer - London Research Facility of Proteome Sciences PLC. Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, in protein mass spectrometry. He was involved in the establishment of the new leading edge protein separation and mass spectrometry facility at the Institute of Psychiatry, King’s College London. His research team is involved in biomarker discovery, validation and assay development. His academic qualifications include a Master of Science (MSc) in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry (GRSC) in 1992. He obtained a PhD in Applied Proteomics at King’s College, London in 2009..

Glenn Barney

Mr. Glenn Barney is Vice President - Business Development, USA of Proteome Sciences PLC. Glenn brings over 25 years of sales and business development experience with global life sciences companies, with strong biomarker focus. He was formerly VP Business Development at NextGen Sciences Inc. and held senior positions at Decision Biomarkers and Parkin Elmer Inc. Mr. Barney holds a BA in Biology from Boston University..

Josef Schwarz

Dr. Josef Schwarz is Head - Projects & Production, Proteome Sciences R&D of Proteome Sciences PLC. Joseph Schwarz joined the Group in summer 2002 when Xzillion, the former proteomics division of Aventis Research and Technologies, was acquired by Proteome Sciences plc. He worked for Aventis/Hoechst Research and Technologies for 6 years, initially as head of mass spectrometry and later as research collaboration project leader. He was instrumental in the establishment of the integrated high throughput 2DE/mass spectrometry proteomics platform at the Frankfurt research facility. Josef Schwarz holds a PhD in organic chemistry/mass spectrometry from the Technical University of Berlin, Germany and a MBA from the University of Durham, UK. He is an author of a number of publications and co-inventor of patents

Gee See Chee

Dr.Chee Gee See is a director of Personalised Medicine of Proteome Sciences PLC .he s a biomarker and translational medicine expert, a former Biomarker and Experimental Medicine Leader for 5 years at Roche in multiple therapeutic areas including CNS, cardiovascular, respiratory and inflammation. Most notable was his role as the clinical oncology biomarker leader for the pivotal Phase III ToGA Herceptin trial and the co-development of the HER2 companion diagnostic in gastric cancer. Prior to this Chee Gee spent 11 years at Glaxo Smith Kline where he was the European Therapeutic Area Analyst for Genetics Research reporting to Dr Allen Roses. He has specialist expertise in regulatory affairs and value-based drug pricing, reimbursement and market access.

William Dawson

Professor William Dawson is Non-Executive Director of Proteome Science PLC. Professor William Dawson retired from Eli Lilly and Company in August 1996 after 27 years’ service, 14 as Research Director in the UK and latterly as Director of Technology Acquisition, Europe. He is a Director of Bionet Limited, Pharmovation Limited, Novolytics Limited,Antitope Limited and a Fellow of the Royal Pharmaceutical Society and of the Royal Society of Chemistry.

Roger McDowell

Mr. Roger Steven McDowell is a Non-Executive Director of the Company. He has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

Basic Compensation

Name Fiscal Year Total

Christopher Pearce

387,730

James Malthouse

249,262

Ian Pike

213,543

Malcolm Ward

--

Glenn Barney

--

Josef Schwarz

--

Gee See Chee

--

William Dawson

--

Roger McDowell

--
As Of 30 Dec 2013

Options Compensation

Search Stocks